All In Biotech

Drug Trial Radar · NCT07628985

BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) in Latin American Adults With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

374

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Carnot LaboratoriesIndustry
Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer are: Does Bofanglutide (GZR18) provide glycemic control comparable to Semaglutide based on changes in HbA1c? Is Bofanglutide (GZR18) safe and well tolerated in the study population? Can participants achieve glycemic targets and improve metabolic outcomes during treatment? Researchers will compare participants receiving Bofanglutide (GZR18) with participants receiving Semaglutide to evaluate their effects on glycemic control, metabolic outcomes, safety, quality of life, and treatment satisfaction. Participants will: Be randomly assigned in a 1:1 ratio to receive Bofanglutide (GZR18) or Semaglutide. Continue stable metformin monotherapy during the study. Receive subcutaneous study treatment with dose escalation according to the study protocol. Participate in 30 weeks of active treatment. Attend scheduled study visits, laboratory assessments, and safety evaluations. Complete questionnaires related to quality of life and treatment satisfaction.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • BofanglutideBiological

    Long-acting GLP-1 receptor agonist administered as a subcutaneous injection every two weeks with dose escalation from 1.5 mg up to 18 mg according to the study protocol.

  • SemaglutideBiological

    GLP-1 receptor agonist administered as a weekly subcutaneous injection with dose escalation from 0.25 mg up to 1 mg according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30Time frame: Baseline to Week 30

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran

    Mexico City, Mexico

  • Private Practice

    Mexico City, Cuauhtémoc, Mexico

  • Asociación Mexicana para la Investigación Clínica A.C. AMIC

    Pachuca, Hidalgo, Mexico

  • Instituto Jalisciense de Investigación en Diabetes y Obesidad, S.C.

    Guadalajara, Jalisco, Mexico

  • Arechavaleta Granell Maria del Rosario Consultorio de Medicina Especializada

    Guadalajara, Jalisco, Mexico

  • Universidad Autónoma de Nuevo Leon. Facultad de Medicina

    Monterrey, Nuevo León, Mexico

  • Oaxaca Site Management Organization, S.C.

    Oaxaca City, Oaxaca, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.